THE MEDIPHARM CO.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 12:58 am EDT
Share
THE MEDIPHARM CO.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 1,166.91 million compared to KRW 863.57 million a year ago. Net income was KRW 3,077.59 million compared to net loss of KRW 16,294.76 million a year ago. Basic earnings per share from continuing operations was KRW 34 compared to basic loss per share from continuing operations of KRW 193 a year ago. Basic earnings per share was KRW 34 compared to basic loss per share of KRW 193 a year ago.
For the six months, sales was KRW 4,363.75 million compared to KRW 1,545.83 million a year ago. Net income was KRW 2,143.92 million compared to net loss of KRW 19,335.66 million a year ago. Basic earnings per share from continuing operations was KRW 25 compared to basic loss per share from continuing operations of KRW 233 a year ago. Basic earnings per share was KRW 25 compared to basic loss per share of KRW 233 a year ago.
SMeDi Co Ltd, formerly The MediPharm Co Ltd, is a Korea-based company primarily engaged in the pharmaceutical distribution business. The Company operates through five segments. The Pharmaceuticals Business segment is engaged in the distribution of pharmaceuticals including recapsules and tablets. The Medical Business segment is engaged in the distribution of medical devices and medical supplies. The Wireless Device segment is engaged in the manufacture of wearable wireless devices. The Video Content segment is engaged in the production of video products. The Investment segment is engaged in the management consulting and investment businesses.